French Launch For R-PR's Sparfloxacin

2 October 1994

Rhone-Poulenc Rorer's new quinolone antibiotic, sparfloxacin, has been launched in France, under the tradename Zagam. This is the second market for the drug; it was first approved last year in Japan under the tradename Spara by original developer Dainippon.

Zagam will be marketed in France by R-PR subsidiary Laboratoires Specia. The initial indications for the drug are community-acquired pneumonia, exacerbations of chronic obstructive bronchopulmonary infections and purulent acute sinusitis. The drug is priced at 218.3 French francs, ($41.13) for a course of six tablets, and is reimbursed at the 65% level.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight